GlassScriptPhysician profile
Francisco Ruiz
NPI 1861430134
$1,131.86
in general payments reported to CMS, 2019-2025
15 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.96 · 2021: $153 · 2022: $369 · 2023: $22.87 · 2024: $216 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $257.89 | 2022-2024 | Exalt Model D |
| E.R. Squibb & Sons, L.L.C. | $170.56 | 2022 | |
| Phathom Pharmaceuticals, INC. | $126.86 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $122.88 | 2021 | |
| Pfizer INC. | $121.68 | 2025 | |
| Genzyme Corporation | $103.56 | 2024 | |
| Abbvie INC. | $60.29 | 2021-2025 | |
| Celltrion USA INC. | $41.45 | 2025 | Vegzelma |
| Celgene Corporation | $24.03 | 2022 | |
| Novo Nordisk INC | $22.87 | 2023 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.46 | 2019 | |
| Amgen INC. | $17.42 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $16.41 | 2025 | Exparel |
| Janssen Biotech, INC. | $15.47 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisco Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.